Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

NCT06062498 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06062498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06062498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Recruiting
Start date
September 29, 2023
Completion date
July 1, 2029
Enrollment
174 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancerv, estrogen-receptor-positive breast cancer, her2/neu-negative breast cancer, metastatic breast cancer